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DexmedetomidineAbstract Background: Laparoscopy results in pathophysiologic changes and potentiates a neuro-
hormonal stress response which increases systemic vascular resistance, mean arterial blood pressure,
and heart rate and the aim of present study was to evaluate the effect of dexmedetomidine in high
risk cardiac patients undergoing laparoscopic cholycystectomy.
Methods: The study included 80 patients [cardiac patient with ASA physical status III–IV], and
scheduled for elective laparoscopic cholycystectomy. The patients were classified randomly into
two groups: Group D: The patients received a loading dose of 1 lg/kg dexmedetomidine over
15 min before induction and maintained with 0.3 lg/kg/h infusion during the procedure. Group
C: The patients received an equal volume of normal saline.
Results: The heart rate increased greatly after induction in the control group compared to the
group D (P< 0.05) and the heart rate remained elevated during the procedures and post-
operatively. There was an attack of tachycardia affected 4 patients in group D and 10 patients in
group C and the comparison was significant (P= 0.044). The mean arterial blood pressure
increased greatly after induction in the control group compared to the group D (P< 0.05) and
the mean arterial blood pressure remained elevated during the procedures and post-anesthesia care
unit The total fentanyl dose was higher in the group C patients more than group D (P< 0.001).
The end-tidal sevoflurane was lower in group D patients than group C patients (P< 0.001).
Conclusion: Dexmedetomidine is safe for cardiac patients undergoing laparoscopic cholycystec-
tomy. It minimized the changes in heart rate and blood pressure and decreased the total dose of
fentanyl and end-tidal sevoflurane and the requirement for medications in high risk cardiac patients.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.52971.
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Laparoscopy has now become the standard technique for
cholycystectomy. Pneumoperitoneum required for laparo-
scopy results in pathophysiologic changes and potentiates a
neurohormonal stress response which increases the systemic
vascular resistance, arterial blood pressure, and heart rate
[1–3], and reduces the venous return, preload, stroke volume,
and cardiac output [4,5]. These factors increase the afterload
and decreases the preload which are tolerated in ASA I and
II patients [6,7], and poorly tolerated by patients with cardiac
dysfunction (ASA III–IV) [8,9].
Dexmedetomidine is a highly selective alpha-2 agonist that
provides sedation and analgesia. It activates pro-survival
kinases and attenuates ischemia and hypoxic injury, including
cardioprotection [10]. Concurrent infusion during surgery
reduces anesthetic consumption by 20–50% [11], and produces
a decrease in heart rate and blood pressure that may be advan-
tageous in ischemic heart disease by improving oxygen supply
and demand balance [12].
The aim of the present study was to evaluate the effect of
dexmedetomidine on the intraoperative hemodynamic stability
in high risk cardiac patients undergoing laparoscopic
cholycystectomy.
2. Methods and patients
After approval from the local ethics committee and obtaining
written informed consent in the King Fahd hospital, Saudi
Arabia, a study included 80 patients [cardiac patient with
ASA physical status III–IV], undergoing elective laparoscopic
cholycystectomy through 2012–2014. The inclusion criteria
were patients with hypertension, coronary artery disease
(ischemic heart disease or percutaneous transluminal coronary
angioplasty, coronary artery bypass grafting), poor ventricular
function, or valvular disease.
The patients were assessed using New York Heart Associa-
tion (NYHA) [13], and American Society of Anesthesiologists
Physical Status Score (ASA) [14]. Exclusion criteria included
patients with congestive heart failure, obese patients or emer-
gency. All patients were evaluated preoperatively by cardiolo-
gists and anesthesiologists. Investigations such as ECG and
transthoracic echocardiography were done for all patients for
evaluating the function of the myocardium and cardiac valves,
diagnosis and treatment of ischemic heart diseases and patients
on anticoagulants were managed by cardiologist preopera-
tively. All patients received their medications for hypertension,
ischemic heart disease, or arrhythmia approximately two hours
prior to anesthesia induction. The patients were classified ran-
domly by simple randomization through a process of coin-
tossing into two groups:
Group D: The patients received dexmedetomidine as a
loading dose of 1 lg/kg over 15 min before induction and
maintained with 0.3 lg/kg/h infusion during the procedure.
Group B (control group): The patients received equal
amount of normal saline.
2.1. Anesthetic technique
For all patients and under local anesthesia, a radial arterial
cannula and peripheral venous cannula G 18 or 16 wereinserted and central venous line was inserted after induction
for administration of inotropic drugs and vasodilators if
needed. Anesthesia induction was started by preoxygenation
with 100% oxygen, intravenous fentanyl (1–2 lg/kg), etomi-
date (0.3 mg/kg), and cisatracurium (0.2 mg/kg). After tracheal
intubation, the anesthesia was maintained with sevoflurane
(1–3%), fentanyl infusion (1–3 lg/kg/h), cisatracurium
(1–2 lg/kg/min) and oxygen:air (50:50%).
For all patients, carbon dioxide insufflation was initiated
and maintained at 5 L/min and the highest limit of intra-
abdominal pressure was kept at 10 mmHg and the surgery
was done in the supine position. Intraoperative fluids were
given cautiously. Intraoperative increased heart rate and sys-
temic hypertension were managed by bolus doses of fentanyl
(1–2 lg/kg) and increasing of sevoflurane concentration 1–
2%, and if hypertension persists, nitroglycerine infusion 0.5–
1 lg/kg/min was started. Intraoperative hypotension was man-
aged by bolus doses of ephedrine 5–10 mg and if persisted,
dopamine infusion was started. At the end of the intervention
and deflation of peritoneum, dopamine infusion was weaned
gradually and discontinued in the operative room. The patients
were transferred to post-anesthesia care unit with closed mon-
itoring and observation for 2–4 h. Most of the patients were
shifted to the ward, while few patients were transferred to
the intensive care unit according to preoperative plan.
2.2. Monitoring of patients
The monitors included the heart rate, mean arterial blood
pressure (MAP), a continuous electrocardiograph with auto-
matic ST-segment analysis (leads II and V), arterial oxygen
saturation, end-tidal carbon dioxide, end tidal sevoflurane,
total dose of fentanyl, arterial blood gases. The heart rate
and mean blood pressure were serially collected at the baseline;
after induction of anesthesia; every 5 min during the
procedure; at the end of surgery; and every 5 min in the
post-anesthetic care unit. Also the incidence of hypotension,
hypertension, tachycardia or bradycardia, and any adverse
effects were recorded.
2.3. Outcomes
The primary outcome was stability of the hemodynamic status
of the patients assessed by changes in the heart rate and blood
pressure.
Secondary outcomes were total dose of fentanyl and end-
tidal sevoflurane %. The safety of the procedure was assessed
by the occurrence of any adverse events and the requirements
to pharmacological support.
2.4. Sample size calculation
Power analysis was performed using Chi square test for inde-
pendent samples on frequency of patients complaining of peri-
operative hemodynamic instability, because it was the main
outcome variable in the present study. A pilot study was done
before starting this study because there are no available data in
the literature for the role of dexmedetomidine in high risk car-
diac patients undergoing laparoscopic cholycystectomy. The
results of the pilot study showed incidence of hemodynamic
instability was of 20% in dexmedetomidine group, and 50%
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Figure 1 CONSORT diagram for the flow of participants through each stage of the present study.
Dexmedetomidine and high risk cardiac patients 177in control group. Taking power 0.8 and alpha error 0.05, a
minimum sample size of 38 patients was calculated for each
group. The total number of patients in each group was 40 to
compensate for possible dropouts.
2.5. The statistical paragraph in material and methods
Data were statistically described in terms of mean ± standard
deviation (±SD), median and range, or frequencies (number
of cases) and percentages when appropriate. Comparison of
numerical variables between the study groups was done using
Student t test for independent samples. For comparing cate-
gorical data, Chi square (v2) test was performed. Exact test
was used instead when the expected frequency is less than 5.
P values less than 0.05 was considered statistically significant.All statistical calculations were done using computer program
SPSS (Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) release 15 for Microsoft Windows (2006).
3. Results
Fig. 1 shows the CONSORT diagram for the flow of partici-
pants through each stage of the present study.
There was no statistical difference regarding the age,
weight, gender, preoperative co-morbidities, ejection fraction
and ASA physical status of patients (P> 0.05) (Table 1).
Table 2 shows the comparison of heart rate between the two
groups. The heart rate increased greatly after induction in
the group C compared with the group D (P< 0.05) and the
heart rate remained elevated during the procedures and
Table 1 Preoperative data of patients. Data are presented as mean ± SD, number,%.
Variables Group A (n= 40) Group B (n= 40) P-value
Age (year) 59.70 ± 9.17 60.17 ± 9.09 0.816
Weight (kg) 77.45 ± 12.92 76.92 ± 12.01 0.662
Gender
Male 15 18 0.495
Female 25 22 0.357
Diabetes mellitus 32 36 0.210
Ejection fraction (%) 38.54 ± 4.94 38.75 ± 5.21 0.965
Atrial fibrillation 4 2 0.323
Ischemic heart disease 17 14 0.491
PCTA 7 5 0.754
CABG 3 2 0.213
Valvular disease 2 1 1.000
ASA III 24 27 0.485
ASA IV 16 13 0.437
PCTA: Percutaneous transluminal coronary angioplasty, CABG: Coronary artery bypass grafting, ASA: American Society of Anesthesiologists
Physical Status Score.
Table 2 Heart rate of patients. Data are presented as mean ± SD.
Timepoints T0 T1 T2 T3 T4
Group A (n= 40) 72.02 ± 9.56 74.72 ± 8.84 70.25 ± 8.43 69.22 ± 10.17 70.42 ± 8.58
Group B (n= 40) 70.15 ± 10.36 90.02 ± 9.43 91.00 ± 8.0 81.00 ± 10.62 83.11 ± 9.04
P-value 0.990 0.024 0.001 0.032 0.047
T0: Baseline reading, T1: reading after induction, T2: reading 30 after induction, T3: reading at the end of surgery, T4: reading in the post-
anesthesia care unit.
Table 3 Mean arterial blood pressure of patients. Data are presented as mean ± SD.
Timepoints T0 T1 T2 T3 T4
Group A (n= 40) 97.28 ± 5.59 93.17 ± 4.54 95.57 ± 3.92 92.02 ± 3.45 93.10 ± 4.46
Group B (n= 40) 97.25 ± 5.62 114.00 ± 4.20 115.12 ± 3.33 106.05 ± 3.39 104.90 ± 4.22
P-value 0.984 0.002 0.004 0.001 0.001
T0: Baseline reading, T1: reading after induction, T2: reading 30 after induction, T3: reading at the end of surgery, T4: reading in the post-
anesthesia care unit.
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affected 4 patients in group D and 10 patients in group C
and the comparison was significant (P= 0.044) (Table 4).
Table 3 shows the comparison of mean arterial blood pressure
of patients between the two groups. The mean arterial blood
pressure increased greatly after induction in the group C com-
pared with the group D (P< 0.05) and the mean arterial
blood pressure remained elevated during the procedures and
post-anesthesia care unit. There was attack of hypertension
included 5 patients in group D and 14 patients in group C
(P= 0.035). There were 6 patients in group D and 4 patients
in group C suffered from hypotension and the comparison was
statistically insignificant (P= 0.735) (Table 4). Table 4 shows
the intraoperative data of patients. There was no statistical dif-
ference regarding the duration of anesthesia (P= 0.846) and
end-tidal carbon dioxide (P= 0.530). Ephedrine was need to
manage hypotension in 6 patients in group D and 4 patients
in group C and the comparison was insignificant
(P= 0.735). Dopamine was needed to manage hypotensionin 3 patients in group D and 2 patients in group C and the
comparison was statistically insignificant (P= 0.213). The
total fentanyl dose was higher in the group C more than group
D (P< 0.001). The end-tidal sevoflurane was lower in group
D patients than group C patients (P< 0.001). There was only
one patient in group C suffered from acute myocardial infarc-
tion and the patient died through a few hours after infarction.4. Discussion
The previous studies evaluated the effect of dexmedetomidine
on ASA physical status I–II and there is not any study on car-
diac patients ASA III–IV during laparoscopic cholycystec-
tomy; therefore, the present study was done to assess the
effect of dexmedetomidine in high risk cardiac patients during
laparoscopic cholycystectomy.
The present study showed that dexmedetomidine is safe for
cardiac patients who underwent laparoscopic cholycystec-
Table 4 Intraoperative data and outcome of patients. Data are presented as mean ± SD, number.
Variables Group A (n= 40) Group B (n= 40) P-value
Duration 93.50 ± 15.19 92.87 ± 13.62 0.846
Hypertension (SAPP 20% above Baseline) 5 14 0.035
Hypotension (SAP 6 20% below Baseline) 6 4 0.735
Tachycardia (HR> 100 bpm) 4 10 0.044
Bradycardia (HR< 60 bpm) 2 1 1.000
Total dose of fentanyl (lg) 124.00 ± 31.62 215.30 ± 42.12 0.001
End-tidal carbon dioxide (mmHg) 30.24 ± 3.15 31.51 ± 3.73 0.530
End tidal sevoflurane (%) 1.59 ± 0.71 1.98 ± 0.76 0.003
Ephedrine 6 4 0.735
Acute MI – 1 1.000
Mortality – 1 1.000
SAP: Systolic arterial pressure; HR: Heart rate; Acute MI: Acute myocardial infarction.
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were minimal changes in heart rate and arterial blood pressure
with dexmedetomidine compared to the control group. There
were no changes in the ST-segment during the procedure.
There were fewer patients suffering from hypertension with
dexmedetomidine than the control group. The total dose of
fentanyl and end-tidal sevoflurane decreased greatly with
dexmedetomidine than the control group. There was only
one mortality case in the control group. The patient was hyper-
tensive preoperatively and hemodynamically stable during the
surgery and recovery. After 6 h from transferring to the ward,
the patient complained of epigastric pain (not chest pain), and
ECG showed massive myocardial infarction. The patient dete-
riorated rapidly in spite of the inotropic support; therefore, the
coronary catheterization could not be done and the patient
expired within 4 h later.
Li-rong et al. [15] evaluated the myocardial protective effect
of dexmedetomidine during non-cardiac surgery in patients
ASA II–III with coronary heart disease undergoing elective
upper abdominal surgery. They found that patients were
hemodynamic stable and the incidence of tachycardia and
myocardial ischemia was significantly lower with dexmedeto-
midine. A large cohort study included 15,656 non-cardiac sur-
gical cases, of whom 2688 received dexmedetomidine
preoperatively or intraoperatively and 12,968 did not receive
dexmedetomidine. There was no significant intraoperative
hypotension or bradycardia with dexmedetomidine [16].
Xu et al. [17] studied the effects of dexmedetomidine on
perioperative myocardial injury by observing peripheral circu-
latory changes in myocardial enzyme levels and hemodynamic
changes in patients with coronary heart disease undergoing
elective hip replacement surgery. Dexmedetomidine reduced
myocardial injury and the patients were hemodynamically
stable. Sadhu et al. [18] studied 28 patients NYHA II–III with
a significant cardiac dysfunction (ejection fraction 20–40%,
cardiomyopathy, valvular disease, heart block, prior cardiac
interventions) and scheduled for laparoscopic cholycystec-
tomy. The anesthesia was maintained with either sevoflurane
or isoflurane without dexmedetomidine. The commonest and
significant events were hypertension, hypotension, tach-
yarrhythmia and bradycardia and the patients required nitro-
glycerine, epinephrine, norepinephrine, and amiodarone
infusion according to the complication and there was onemortality case as a result of acute myocardial infarction (third
postoperative day), and other studies showed the same results
[19,20].
Sidorowicz et al. [21] found that patients ASA II–III who
received dexmedetomidine during carotid endarterectomy were
hemodynamically stable and there were no fluctuation in the
blood pressure compared to patients who did not receive
dexmedetomidine.
The present study and other studies showed that
dexmedetomidine is protective for the cardiovascular system
in cardiac patients undergoing non-cardiac surgery.
Dexmedetomidine decreases stress hormones (epinephrine,
norepinephrine, vasopressin) during pneumoperitoneum
[3,22–24], and these hormones cause tachycardia, hypertension
and perioperative myocardial infarction [25–29]. Also the
dexmedetomidine has an antiarrhythmic effect [29–33], and
decreases the dose of anesthetics and narcotics that may affect
the hemodynamic stability in cardiac patients during laparo-
scopic cholycystectomy [34–36].
Against the results of the present study, a meta-analysis
study included 840 patients and evaluated the cardiac out-
comes of dexmedetomidine following non-cardiac surgery
and showed that dexmedetomidine is associated with signifi-
cant perioperative hypotension, myocardial ischemia and
bradycardia and anticholinergic did not reduce the incidence
of bradycardia associated with dexmedetomidine [12].
The present study recognizes some limitations such as a
being single center study as well the small number of patients.
5. Conclusion
Dexmedetomidine is safe for cardiac patients undergoing
laparoscopic cholycystectomy. It minimized the changes in
heart rate and blood pressure and decreased the total dose of
fentanyl, end-tidal sevoflurane and the requirement for medi-
cations in high risk cardiac patients without complications
related to dexmedetomidine.
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